MTOR and thyroid cancer: Many literature reports (Ji et al. 2017; Woo et al. 2017) confirm the antitumour efficacy of mTOR inhibitor – rapamycin or another rapalog in combination with highly selective AKT inhibitor – MK2206 in inhibition of proliferation, tumour growth and induction of apoptosis in many types of cancers such as: lymphoblastic leukemia, cholangiocarcinoma, hepatocellular carcinoma, neuroblastoma, gastric cancer, and thyroid cancer.